NASDAQ:MIRA MIRA Pharmaceuticals Q2 2025 Earnings Results & Report $0.66 -0.02 (-3.52%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$0.65 -0.01 (-1.84%) As of 05:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. MIRA Pharmaceuticals beat analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.09 versus the -$0.11 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 14, 2025TimeBefore Market Opens MIRA Pharmaceuticals EPS ResultsActual EPS-$0.09Consensus EPS -$0.11Beat/MissBeat by +$0.02One Year Ago EPSN/AEPS Beat Rate4 of last 7 quartersMIRA Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsMIRA Pharmaceuticals' next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile MIRA Pharmaceuticals Q2 2025 Earnings FAQ Did MIRA Pharmaceuticals beat earnings estimates for Q2 2025? MIRA Pharmaceuticals (NASDAQ:MIRA) reported earnings of -$0.09 per share for Q2 2025, beating the consensus estimate of -$0.11. The report was announced on Thursday, August 14, 2025. When is MIRA Pharmaceuticals' next earnings date? MIRA Pharmaceuticals' next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for MIRA Pharmaceuticals on the company's earnings history page. MIRA Pharmaceuticals Earnings HeadlinesMIRA Pharmaceuticals consensus price target increased by 16.67% to $3.57October 3, 2026 | msn.comMaxim Initiates MIRA Pharmaceuticals at Buy With $3.50 Price TargetSeptember 18, 2026 | marketscreener.comMA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need.October 16 at 1:00 AM | Investors Alley (Ad)MIRA Advances Phase 2a Study Of Ketamir-2 For Chemotherapy-Linked Neuropathy; Stock UpSeptember 17, 2026 | rttnews.comMIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA ReviewSeptember 17, 2026 | globenewswire.comMIRA-55 toxicology results advance non-opioid pain programSeptember 1, 2026 | tipranks.comSee More MIRA Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MIRA Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MIRA Pharmaceuticals and other key companies, straight to your email. Email Address About MIRA PharmaceuticalsMIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s pipeline is centered on novel pharmaceutical compounds intended to address conditions involving anxiety, cognitive impairment, depression and pain. MIRA’s lead programs include MIRA-1a, an investigational synthetic cannabinoid designed for potential use in neurological and psychiatric conditions, and MIRA-3, an oral ketamine analog being developed for potential applications in depression and pain management. These candidates remain in development and have not been approved for commercial use. Based in Miami, Florida, MIRA Pharmaceuticals is focused primarily on advancing its drug candidates through preclinical and clinical development rather than selling marketed products. The company is led by Chief Executive Officer Erez Aminov and is pursuing pharmaceutical development opportunities for patients in the United States and broader international markets.View MIRA Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
